The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. entered into an underwritten public offering and a concurrent private placement of its common stock. The company agreed to sell 34,782,609 shares in the offering at $5.75 per share, and granted underwriters a 30-day option for 5,217,391 additional shares, which was exercised in full. It also agreed to sell 15,652,173 shares at $5.75 per share in a private placement to Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc.
The combined transactions are expected to generate approximately $320 million in gross proceeds before fees and expenses. Anteris plans to use the net proceeds, together with existing cash, to support its next stage of growth, including the global pivotal PARADIGM Trial for its DurAVR® Transcatheter Heart Valve, expansion of manufacturing capabilities, funding ongoing research and development for v2vmedtech, inc., and for working capital and other general corporate purposes.
Anteris Technologies Global Corp. entered into an underwritten public offering and a concurrent private placement of its common stock. The company agreed to sell 34,782,609 shares in the offering at $5.75 per share, and granted underwriters a 30-day option for 5,217,391 additional shares, which was exercised in full. It also agreed to sell 15,652,173 shares at $5.75 per share in a private placement to Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc.
The combined transactions are expected to generate approximately $320 million in gross proceeds before fees and expenses. Anteris plans to use the net proceeds, together with existing cash, to support its next stage of growth, including the global pivotal PARADIGM Trial for its DurAVR® Transcatheter Heart Valve, expansion of manufacturing capabilities, funding ongoing research and development for v2vmedtech, inc., and for working capital and other general corporate purposes.
Anteris Technologies Global Corp. is issuing 34,782,609 shares of common stock at $5.75 per share in a primary public offering on Nasdaq. The deal is expected to raise approximately $189.8 million in gross proceeds before expenses, with net proceeds estimated at about $187.4 million, or $215.6 million if underwriters fully exercise a 5,217,391‑share option. Concurrently, a Medtronic plc subsidiary has agreed to buy 15,652,173 additional shares in a private placement at the same price, with expected net proceeds of about $84.4 million that are not registered in this prospectus.
After the offering and private placement, Anteris expects to have 86,497,152 shares outstanding, including CDIs. Proceeds, together with existing cash, will fund the PARADIGM pivotal trial of the DurAVR THV system for severe aortic stenosis, expand manufacturing capacity, and support R&D, including for v2vmedtech, plus working capital. The company is a development‑stage structural heart business with preliminary cash of about $12.6 million as of December 31, 2025 and an auditor going‑concern explanatory paragraph, and it acknowledges that investors in this offering will experience immediate dilution of $2.50 per share.
BlackRock, Inc. has updated its ownership disclosure for Anteris Technologies Global Corp common stock. BlackRock reports beneficial ownership of 2,026,967 shares, representing 4.9% of the outstanding common stock. It reports sole voting power over 1,997,796 shares and sole dispositive power over the full 2,026,967 shares, with no shared voting or dispositive power.
The filing explains that these holdings are attributed to certain BlackRock business units, and do not include any securities held by other disaggregated units. Various underlying persons have the right to receive dividends or sale proceeds from these shares, but no single person has more than five percent of the total outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Anteris Technologies Global Corp. is registering $200,000,000 of common stock in a primary offering. The company has also granted underwriters a 30-day option to buy up to an additional $30,000,000 of common stock. Concurrently, a Covidien subsidiary of Medtronic may purchase up to $90.0 million of common stock in a private placement at the same price as this offering, for a stake between 16.0% and 19.99% of shares outstanding after the deals close.
Anteris develops the DurAVR THV System for treating severe aortic stenosis and is running the global PARADIGM pivotal trial following FDA IDE and initial European approvals. The company remains a development-stage business with recurring losses and preliminary cash and cash equivalents of about $12.6 million as of December 31, 2025, and its auditors have raised substantial doubt about its ability to continue as a going concern. Proceeds from this offering and the private placement are intended to fund PARADIGM trial execution, manufacturing expansion, R&D for v2vmedtech and general corporate purposes, and Anteris is also exploring up to $100 million of additional debt financing.
Anteris Technologies Global Corp. is registering $200,000,000 of common stock in a primary offering. The company has also granted underwriters a 30-day option to buy up to an additional $30,000,000 of common stock. Concurrently, a Covidien subsidiary of Medtronic may purchase up to $90.0 million of common stock in a private placement at the same price as this offering, for a stake between 16.0% and 19.99% of shares outstanding after the deals close.
Anteris develops the DurAVR THV System for treating severe aortic stenosis and is running the global PARADIGM pivotal trial following FDA IDE and initial European approvals. The company remains a development-stage business with recurring losses and preliminary cash and cash equivalents of about $12.6 million as of December 31, 2025, and its auditors have raised substantial doubt about its ability to continue as a going concern. Proceeds from this offering and the private placement are intended to fund PARADIGM trial execution, manufacturing expansion, R&D for v2vmedtech and general corporate purposes, and Anteris is also exploring up to $100 million of additional debt financing.
Anteris Technologies Global Corp. reported an equity transaction by its Chief Operating Officer and director. On December 16, 2025, the reporting person acquired 166,666 shares of common stock through the vesting and settlement of restricted stock units, recorded as a code "M" transaction. On the same date, 65,584 shares were disposed of in a code "F" transaction at a price of $4.95 per share, typically reflecting shares withheld to cover taxes. After these transactions, the reporting person directly held 101,082 shares of common stock.
The derivative table shows this activity came from a grant of 500,000 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16 of 2025, 2026, and 2027, subject to continued service. Following the reported transaction, 333,334 restricted stock units remained beneficially owned.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported the vesting of a portion of his equity award and the related share issuance. On December 16, 2024, he was granted 83,333 restricted stock units (RSUs), scheduled to vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to his continued service. On December 16, 2025, 27,777 RSUs vested and converted on a one-for-one basis into common stock, recorded as an acquisition of 27,777 shares at a price of $0.
Following this transaction, McDonnell beneficially owns 27,777 common shares indirectly through Citicorp Nominees Pty Ltd and 55,556 RSUs directly, each RSU convertible into one share of common stock. The common stock received is represented as CHESS Depositary Interests traded on the Australian Securities Exchange.
Anteris Technologies Global Corp. chief executive officer and director Wayne Paterson reported equity award activity involving the company’s common stock. On December 16, 2025, a tranche of 333,333 restricted stock units (RSUs) converted on a one-for-one basis into the same number of common shares, reflecting previously granted equity compensation.
The filing also shows a disposition of 163,213 common shares at $4.95 per share, typically consistent with share sales to cover tax withholding on vested awards. After these transactions, Paterson held 182,727 common shares indirectly through Citibank, N.A. London as custodian and 20,334 shares directly, along with 666,667 RSUs that remain outstanding. These RSUs are part of a 1,000,000-unit grant awarded on December 16, 2024, vesting in roughly equal installments on December 16 of 2025, 2026, and 2027, which stockholders approved on December 3, 2025.
Anteris Technologies Global Corp. director John Seaberg reported the vesting and conversion of restricted stock units into common stock. On 12/16/2025, 27,777 restricted stock units were converted into 27,777 shares of common stock in a transaction coded "M," increasing his directly held common shares to 43,635. He also holds 3,852 shares indirectly through Citibank, N.A. London as custodian.
The derivative table shows these 27,777 restricted stock units converting at an exercise price of $0 into common stock, leaving 55,556 restricted stock units beneficially owned following the transaction. These units come from a contingent grant of 83,333 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to continued service and approval previously obtained from stockholders on December 3, 2025.
Anteris Technologies Global Corp. filed a prospectus supplement linked to its Form S-1 registration statement covering up to 9,103,796 shares of common stock that may be sold from time to time by selling stockholders. The supplement incorporates information from a newly filed Current Report on Form 8-K.
The attached 8-K notes that on December 13, 2025 (December 14, 2025 in Australia), Stephen Denaro resigned, with immediate effect, from the Company’s Board of Directors as a Class II director, and his resignation was not due to any disagreement over operations, policies or practices. He will continue as corporate secretary of Anteris Technologies Pty Ltd and as a director of that and other Australian subsidiaries. The Company’s common stock trades on Nasdaq under the symbol AVR, which closed at $4.98 per share on December 12, 2025.
Anteris Technologies Global Corp. disclosed that Stephen Denaro resigned from its Board of Directors and as a Class II director, effective December 13, 2025. The company states that his resignation is not due to any disagreement with management or with its operations, policies, or practices, suggesting no underlying dispute at the board level.
Denaro will remain closely involved with the organization as corporate secretary of Anteris Technologies Pty Ltd and as a member of the boards of that company and other Australian subsidiaries. This shifts the composition of the U.S. parent’s board while maintaining leadership continuity within Anteris’s Australian entities.